Using controlled clinical trials to learn more about acute drug-induced liver injury
- 13 October 2008
- journal article
- meeting report
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 48 (5), 1680-1689
- https://doi.org/10.1002/hep.22633
Abstract
Drug‐induced liver injury (DILI) is of major interest to hepatologists and clinicians in general, patients, government regulators, and the pharmaceutical industry. Understanding why this form of injury occurs only in certain individuals has major implications for the development and availability of drug therapies and in the prevention of these events. A single controlled clinical trial may be unlikely to show cases of such rare events, but in the aggregate, clinical trials offer a unique resource for learning more about individual susceptibility and developing truly predictive new biomarkers for DILI. We pose the question as to whether clinical trials could be modified or improved to provide data that would better answer some of the outstanding issues. At a recent (March 2008) public meeting, experts from academia, industry, and regulatory bodies discussed several major issues regarding liver safety in clinical trials including: what signals of liver injury should justify stopping administration of study drug or allowing it to continue; if deliberate rechallenge should be done and under what circumstances; whether patients with liver disease should be included in clinical trials; and what kinds of new biomarkers will be needed to answer these questions more clearly. Past clinical trials have not provided data to settle those issues, and reliance has defaulted to consensus of expert opinions. Modified and better clinical trials with standardized collection of data and biospecimens are probably the best source of new and potentially valuable information to supplant current rules based on consensus of expert opinions and to understand by what mechanisms and how to distinguish those individuals who are susceptible to severe DILI. (HEPATOLOGY 2008.)This publication has 37 references indexed in Scilit:
- Isoforms of alanine aminotransferases in human tissues and serum—Differential tissue expression using novel antibodiesArchives of Biochemistry and Biophysics, 2007
- Lymphocyte loss and immunosuppression following acetaminophen-induced hepatotoxicity in mice as a potential mechanism of toleranceChemical Research in Toxicology, 2006
- Insight into hepatotoxicity: The troglitazone experienceHepatology, 2005
- Differential Expression of Mouse Hepatic Transporter Genes in Response to Acetaminophen and Carbon TetrachlorideToxicological Sciences, 2004
- Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United StatesAnnals of Internal Medicine, 2002
- Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: An explanation for high acetaminophen dosage in humans without hepatic injuryHepatology, 1999
- Hepatic Dysfunction Associated with TroglitazoneThe New England Journal of Medicine, 1998
- Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's DiseaseJAMA, 1994
- Acetylation Rates and Monthly Liver Function Tests during One Year of Isoniazid Preventive TherapySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1975
- The Spectrum of HepatotoxicityPerspectives in Biology and Medicine, 1968